Taken together, these mechanistic data and clinical trials support our working hypothesis that a patient’s KIF5B-RET fusion can yield HLA-presentable junctional epitopes suitable for inclusion in a cancer vaccine contingent on restricting predictions to the patient’s HLA type and validating top candidates where feasible. Here, RET is linked to cancer.